The DOI matches its Crossref record; 217 of the 217 references it cites were found in a registry or an index.
Mechanisms of resistance to cisplatin and carboplatin
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mohammad, R. M., Banerjee, S., Li, Y., Aboukameel, A., Küçük, Ö., & Sarkar, F. H. (2006) · Cancer · doi:10.1002/cncr.21731 · Cited by 84
RetractedCisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Herbst, R. S., Prager, D., Hermann, R., Fehrenbacher, L., Johnson, B. E., Sandler, A., Kris, M. G., Tran, H. T., Klein, P., Li, X., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.840 · Cited by 1,490 · cited 1×
“[275] Herbst RS, Prager D, Hermann R, et al.”
BackgroundUptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals
Ishida, S., Lee, J., Thiele, D. J., & Herskowitz, I. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162491399 · Cited by 927
(1990) · PubMed · Cited by 757
Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.9.1618 · Cited by 728
Is Cisplatin-Induced Cell Death Always Produced by Apoptosis?
Gonzalez, V. M., Fuertes, M. A., Alonso, C., & Perez, J. M. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09232-0 · Cited by 578
Safaei, R., Larson, B. J., Cheng, T. C., Gibson, M. A., Otani, S., Naerdemann, W., & Howell, S. B. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0102 · Cited by 564
Teicher, B. A., Lazo, J. S., & Sartorelli, A. C. (1981) · PubMed · Cited by 555
Witta, S. E., Gemmill, R. M., Hirsch, F. R., Coldren, C. D., Hedman, K., Ravdel, L., Helfrich, B., Dziadziuszko, R., Chan, D. C., Sugita, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1988 · Cited by 515
Loss of DNA mismatch repair in acquired resistance to cisplatin.
Aebi, S. P., Kurdi-Haidar, B., Gordon, R. T., Cenni, B., Zheng, H., Fink, D. A., Christen, R. D., Boland, C. R., Koi, M., Fishel, R. A., et al. (1996) · PubMed · Cited by 502
Pastan, I., Gottesman, M. M., Ueda, K., Lovelace, E., Rutherford, A. V., & Willingham, M. C. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4486 · Cited by 484
Taniguchi, K., WADA, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S.-I., & Kuwano, M. (1996) · PubMed · Cited by 470
Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117388 · Cited by 446
Effect of Proton Pump Inhibitor Pretreatment on Resistance of Solid Tumors to Cytotoxic Drugs
Luciani, F., Spada, M., De Milito, A., Molinari, A., Rivoltini, L., Montinaro, A., Marra, M., Lugini, L., Logozzi, M., Lozupone, F., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh305 · Cited by 435
Muizelaar, J. P., Wei, E. P., Kontos, H. A., & Becker, D. P. (1983) · Journal of neurosurgery · doi:10.3171/jns.1983.59.5.0822 · Cited by 421
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy
Reed, E. (1998) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(98)90056-1 · Cited by 397
Recognition and processing of cisplatin- and oxaliplatin-DNA adducts
Chaney, S. G., Campbell, S. L., Bassett, E., & Wu, Y. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.08.008 · Cited by 396
Perego, P., Giarola, M., Righetti, S. C., Supino, R., Caserini, C., Delia, D., Pierotti, M. A., Miyashita, T., Reed, J. C., & Zunino, F. (1996) · PubMed · Cited by 384
for the ‘Tumour and Angiogenesis Research Group’, Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Bougioukas, G., Didilis, V, Gatter, K. C., & Harris, A. L. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601205 · Cited by 377
Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O., & Sarkar, F. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4604 · Cited by 376
Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy
(1991) · Springer eBooks · doi:10.1007/978-1-4899-0738-7 · Cited by 374
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Mann, S. C., Andrews, P. A., & Howell, S. B. (1990) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00684878 · Cited by 349
Mondesire, W. H., Jian, W., Zhang, H., Ensor, J., Hung, M.-C., Mills, G. B., & Meric-Bernstam, F. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0361 · Cited by 319
Notarbartolo, M., Poma, P., Perri, D., Dusonchet, L., Cervello, M., & D'Alessandro, N. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.10.051 · Cited by 317
Enhancement of chemotherapy by manipulation of tumour pH
Raghunand, N., He, X., Sluis, R. V., Mahoney, B., Baggett, B., Taylor, C. W., Paine-Murrieta, G., Roe, D., Bhujwalla, Z. M., & Gillies, R. J. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690455 · Cited by 316
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer
Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M. S., Queralt, C., Majo, J., Sanchez, J. M., Sanchez, J. J., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh260 · Cited by 307
Naumov, G. N., Townson, J. L., MacDonald, I. C., Wilson, S. M., Bramwell, V. H. C., Groom, A. C., & Chambers, A. F. (2003) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000004377.12288.3c · Cited by 305
ERCC1 and ERCC2 Expression in Malignant Tissues From Ovarian Cancer Patients
Dabholkar, M., Bostick-Bruton, F., Weber, C., Bohr, V. A., Egwuagu, C., & Reed, E. (1992) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/84.19.1512 · Cited by 305
Expression of γ-glutamyltransferase in cancer cells and its significance in drug resistance
Pompella, A., De Tata, V., Paolicchi, A., & Zunino, F. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.10.005 · Cited by 280
HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs.
Garrido, C., Ottavi, P., Fromentin, A., Hammann, A., Arrigo, A., Chauffert, B., & Mehlen, P. (1997) · PubMed · Cited by 279
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair.
Fink, D. A., Zheng, H., Nebel, S., Norris, P. S., Aebi, S. P., Lin, T., Nehmé, A., Christen, R. D., Haas, M., MacLeod, C. L., et al. (1997) · PubMed · Cited by 277
(1981) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/67.3.663 · Cited by 268
Clinical Pharmacokinetics of Carboplatin
van der Vijgh, W. J. F. (1991) · Clinical Pharmacokinetics · doi:10.2165/00003088-199121040-00002 · Cited by 263
The electrophile counterattack response: Protection against neoplasia and toxicity
Prestera, T., Zhang, Y., Spencer, S. R., Wilczak, C. A., & Talalay, P. (1993) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(93)90024-8 · Cited by 256
Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs
Safaei, R., & Howell, S. B. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.09.007 · Cited by 254
The overexpression of specialized DNA polymerases in cancer
Albertella, M. R., Lau, A., & O’Connor, M. J. (2005) · DNA Repair · doi:10.1016/j.dnarep.2005.01.005 · Cited by 250
O'Connell, J. P., Kris, M. G., Gralla, R. J., Groshen, S., Trust, A., Fiore, J. J., Kelsen, D. P., Heelan, R. T., & Golbey, R. B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.11.1604 · Cited by 238
The Copper Transporter CTR1 Regulates Cisplatin Uptake in Saccharomyces cerevisiae
Lin, X., Okuda, T., Holzer, A., & Howell, S. B. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1154 · Cited by 232
Lee, S., Choi, E.-J., Jin, C., & Kim, D.-H. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.11.051 · Cited by 230
Reed, E., Ozols, R. F., Tarone, R., Yuspa, S. H., & Poirier, M. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5024 · Cited by 217
Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models
Mabuchi, S., Ohmichi, M., Nishio, Y., Hayasaka, T., Kimura, A., Ohta, T., Saito, M., Kawagoe, J., Takahashi, K., Yada-Hashimoto, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313709200 · Cited by 211
A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage
Albertella, M. R., Green, C. M., Lehmann, A. R., & O'Connor, M. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1095 · Cited by 207
Ishikawa, T., Wright, C. D., & Ishizuka, H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)62016-8 · Cited by 206
Newell, K., Franchi, A., Pouysségur, J., & Tannock, I. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.3.1127 · Cited by 197
Zhen, W., Link, C. J., O'Connor, P. M., Reed, E., Parker, R., Howell, S. B., & Bohr, V. A. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.9.3689 · Cited by 196
pH and drug resistance in tumors
Raghunand, N., & Gillies, R. J. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0119 · Cited by 194
Rosell, R., Scagliotti, G., Danenberg, K. D., Lord, R. V., Bepler, G., Novello, S., Cooc, J., Crinò, L., Sánchez, J. J., Taron, M., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206419 · Cited by 188
Adaptive response and oxidative stress.
Crawford, D. R., & Davies, K. J. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s1025 · Cited by 188
Chen, K. G., Valencia, J. C., Lai, B., Zhang, G., Paterson, J. K., Rouzaud, F., Berens, W., Wincovitch, S. M., Garfield, S. H., Leapman, R. D., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600213103 · Cited by 186
Biliran, H., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F. H., & Liao, J. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2419 · Cited by 181
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells
Andrews, P., Murphy, M., & Howell, S. (1987) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00254568 · Cited by 176
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease
Williams, J., Lucas, P. C., Griffith, K. A., Choi, M., Fogoros, S., Hu, Y. Y., & Liu, J. R. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.10.026 · Cited by 173
Brozović, A., Fritz, G., Christmann, M., Zisowsky, J., Jaehde, U., Osmak, M., & Kaina, B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20522 · Cited by 172
Characterization of a novel metabolic strategy used by drug‐resistant tumor cells
Harper, M., Antoniou, A., Villalobos‐Menuey, E., Russo, A., Trauger, R., Vendemelio, M., George, A., Bartholomew, R., Carlo, D., Shaikh, A., et al. (2002) · The FASEB Journal · doi:10.1096/fj.02-0541com · Cited by 172
Molecular profiling of platinum resistant ovarian cancer
Helleman, J., Jansen, M. P. H. M., Span, P. N., van Staveren, I. L., Massuger, L. F. A. G., Meijer‐van Gelder, M. E., Sweep, F. C. G. J., Ewing, P. C., van der Burg, M. E. L., Stoter, G., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21599 · Cited by 165
Davies, M. S., Berners-Price, S. J., & Hambley, T. W. (2000) · Inorganic Chemistry · doi:10.1021/ic000847w · Cited by 165
Ferrandina, G. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.973 · Cited by 165
Cheng, J. Q., Jiang, X., Fraser, M. E., Li, M., Dan, H. C., Sun, M., & Tsang, B. K. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00003-1 · Cited by 162
Amantana, A., London, C. A., Iversen, P. L., & Devi, G. R. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.699.3.6 · Cited by 161
Protein phosphatase 4 – from obscurity to vital functions
Cohen, P. T. W., Philp, A., & Vázquez-Martin, C. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.04.070 · Cited by 161
Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation
Houldsworth, J., Xiao, H., Murty, V., Chen, W., Ray, B., Reuter, V. E., Bosl, G. J., & Chaganti, R. (1998) · Oncogene · doi:10.1038/sj.onc.1201770 · Cited by 161
Ferrandina, G., Lauriola, L., Zannoni, G. F., Fagotti, A., Fanfani, F., Legge, F., Maggiano, N., Gessi, M., Mancuso, S., Ranelletti, F. O., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf207 · Cited by 160
Wang, S. J., & Bourguignon, L. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.7.771 · Cited by 157
Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung Cancer
Rosell, R., Tarón, M., Barnadas, A., et al. (2003) · Cancer Control · doi:10.1177/107327480301000404 · Cited by 156
Cancer cell adaptation to chemotherapy
Nicolantonio, F. D., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Palma, S. D., Johnson, P., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-78 · Cited by 153
Cullen, K. J., Newkirk, K. A., Schumaker, L. M., Aldosari, N., Rone, J. D., & Haddad, B. R. (2003) · PubMed · Cited by 151
Elevated expression of vacuolar proton pump genes and cellular ph in cisplatin resistance
Murakami, T., Shibuya, I., Ise, T., Chen, Z., Akiyama, S., Nakagawa, M., Izumi, H., Nakamura, T., Matsuo, K., Yamada, Y., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1418 · Cited by 144
Holzer, A. K., Katano, K., Klomp, L. W. J., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0748 · Cited by 143
Roberts, D., Schick, J. S., Conway, S. R., Biade, S., Laub, P. B., Stevenson, J. P., Hamilton, T. C., O'Dwyer, P. J., & Johnson, S. W. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602447 · Cited by 142
Regulation of intracellular pH in human melanoma: potential therapeutic implications.
Wahl, M., Owen, J. A., Burd, R., Herlands, R., Nogami, S. S., Rodeck, U., Berd, D., Leeper, D. B., & Owen, C. S. (2002) · PubMed · Cited by 141
A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431
Castagna, A., Antonioli, P., Astner, H., Hamdan, M., Righetti, S. C., Perego, P., Zunino, F., & Righetti, P. G. (2004) · PROTEOMICS · doi:10.1002/pmic.200400835 · Cited by 139
Pithi Chanvorachote, B., Nimmannit, U., Stehlik, C., Wang, L., Jiang, B., Ongpipattanakul, B., & Rojanasakul, Y. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4533 · Cited by 136
Cisplatin Resistance and Transcription Factors
Torigoe, T., Izumi, H., Ishiguchi, H., Yoshida, Y., Tanabe, M., Yoshida, T., Igarashi, T., Niina, I., Wakasugi, T., Imaizumi, T., et al. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011053352587 · Cited by 133
DNA Repair capacity and cisplatin sensitivity of human testis tumour cells
Köberle, B., Grimaldi, K. A., Sunters, A., Hartley, J. A., Kèlland, L. R., & Masters, J. R. (1997) · International Journal of Cancer · Cited by 132
Davies, A. M., Ho, C., Lara, P. N., Mack, P. C., Gumerlock, P. H., & Gandara, D. R. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.n.021 · Cited by 131
Katano, K., Safaei, R., Samimi, G., Holzer, A. K., Rochdi, M., & Howell, S. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.2.466 · Cited by 128
Human tissue distribution of platinum after cis-diamminedichloroplatinum
Stewart, D., Benjamin, R., Luna, M. A., Feun, L. G., Caprioli, R. M., Seifert, W. E., & Loo, T. L. (1982) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257239 · Cited by 126
Self-citationCisplatin resistance and oncogenes - a review
Dempke, W. C. M., Voigt, W., Grothey, A. A., Hill, B. T., & Schmoll, H. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200004000-00001 · Cited by 126
Wu, F., Lin, X., Okuda, T., & Howell, S. B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3942 · Cited by 125
Haemodynamic and Transport Barriers to the Treatment of Solid Tumours
Jain, R. K., Cook, A. W., & Steele, E. L. (1991) · International Journal of Radiation Biology · doi:10.1080/09553009114551621 · Cited by 119
Mellor, H. R., Ferguson, D. J. P., & Callaghan, R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602710 · Cited by 117
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
Beale, P. J., Rogers, P., Boxall, F. E., Sharp, S. Y., & Kèlland, L. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0939 · Cited by 112
AKT involvement in cisplatin chemoresistance of human uterine cancer cells
Gagnon, V., Mathieu, I., Sexton, É., Leblanc, K., & Asselin, É. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.06.023 · Cited by 112
Shi, Y., Zhai, H., Wang, X., Han, Z., Liu, C., Lan, M., Du, J.-P., Guo, C., Zhang, Y., Wu, K., et al. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.02.009 · Cited by 111
Abbosh, P. H., Montgomery, J. S., Starkey, J. A., Novotný, M. V., Zuhowski, E. G., Egorin, M. J., Moseman, A. P., Golas, A. A., Brannon, K. M., Balch, C., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3575 · Cited by 109
Byun, S., Kim, S. W., Choi, H., Lee, C., & Lee, E. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05472.x · Cited by 105
Lin, X., & Howell, S. B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0491 · Cited by 104
Yang, X., Zheng, F., Xing, H., Gao, Q., Wei, W., Lu, Y., Wang, S., Zhou, J., Hu, W., & Ma, D. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0556-9 · Cited by 100
Youn, C.-K., Kim, M.-H., Cho, H.-J., Kim, H.-B., Chang, I. Y., Chung, M., & You, H. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0348 · Cited by 99
Carrassa, L., Broggini, M., Erba, E., & Damia, G. L. M. (2004) · Cell Cycle · doi:10.4161/cc.3.9.1080 · Cited by 98
Surowiak, P., Materna, V., Kaplenko, I., Spaczyński, M., Dietel, M., Lage, H., & Zabel, M. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1228-0 · Cited by 98
Polée, M., Hop, W. C. J., Kok, T. C., Eskens, F. A. L. M., van der Burg, M. E. L., Splinter, T. A. W., Siersema, P. D., Tilanus, H. W., Stoter, G., & van der Gaast, A. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601364 · Cited by 97
Materna, V., Liedert, B., Thomale, J., & Lage, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20899 · Cited by 96
Weaver, K. D., Yeyeodu, S. T., Cusack, J. C., Baldwin, A. S., & Ewend, M. G. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1022554824129 · Cited by 95
Ohta, T., Ohmichi, M., Hayasaka, T., Mabuchi, S., Saitoh, M., Kawagoe, J., Takahashi, K., Igarashi, H., Du, B., Doshida, M., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1450 · Cited by 94
Kang, S., Ju, W., Kim, J., Park, N.-H., Song, Y. S., Kim, S. C., Park, S., Kang, S., & Lee, H.-P. (2006) · Experimental & Molecular Medicine · doi:10.1038/emm.2006.38 · Cited by 94
Hypoxia Selection of Death-resistant Cells
Dong, Z., & Wang, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312225200 · Cited by 93
Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.
Rao, P. H., Houldsworth, J., Palanisamy, N., Murty, V. V. V. S., Reuter, V. E., Motzer, R. J., Bosl, G. J., & Chaganti, R. S. K. (1998) · PubMed · Cited by 92
Bergoglio, V., Canitrot, Y., Hogarth, L., Minto, L., Howell, S. B., Cazaux, C., & Hoffmann, J. (2001) · Oncogene · doi:10.1038/sj.onc.1204743 · Cited by 92
Dickson, J. A., & Calderwood, S. K. (1979) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/63.6.1371 · Cited by 87
Yoo, B. C., Ku, J., Hong, S., Shin, Y., Park, S. Y., Kim, H. K., & Park, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11604 · Cited by 87
Perego, P., Romanelli, S., Carenini, N., Magnani, I., Leone, R., Bonetti, A. V., Paolicchi, A., & Zunino, F. (1998) · Annals of Oncology · doi:10.1023/a:1008265012435 · Cited by 86
Nathan, S. S., DiResta, G. R., Casas-Ganem, J. E., Hoang, B. H., Sowers, R., Yang, R., Huvos, A. G., Gorlick, R., & Healey, J. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2048 · Cited by 85
Kozin, S. V., Shkarin, P., & Gerweck, L. E. (2001) · PubMed · Cited by 85
Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin
Belenkov, S., Shenouda, G., Rizhevskaya, E., Cournoyer, D., Belzile, J.-P., Souhami, L., Dević, S., & Chow, T. Y.-K. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1525.3.12 · Cited by 84
Olivero, O. A., Chang, P. K., López‐Larraza, D. M., Semino-Mora, M. C., & Poirier, M. C. (1997) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/s0165-1218(97)00037-2 · Cited by 83
Miyashita, H., Nitta, Y., Mori, S., Kanzaki, A., Nakayama, K., Terada, K., Sugiyama, T., Kawamura, H., Satō, A., MORIKAWA, H., et al. (2003) · Oral Oncology · doi:10.1016/s1368-8375(02)00038-6 · Cited by 83
Biological and chemical inhibitors of NF‐κB sensitize SiHa cells to cisplatin‐induced apoptosis
Manickam, V., Anto, R. J., Nair, S. A., Varghese, M., & Karunagaran, D. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20116 · Cited by 82
Pepponi, R., Marra, G., Fuggetta, M. P., Falcinelli, S., Pagani, E., Bonmassar, E., Jiricny, J., & D’Atri, S. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.043950 · Cited by 81
Yamamoto, K., Okamoto, A., Isonishi, S., Ochiai, K., & Ohtake, Y. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00532-8 · Cited by 81
Causes and consequences of acidic pH in tumors: a magnetic resonance study
Stubbs, M., McSheehy, P. M. J., & Griffiths, J. R. (1999) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(98)00018-1 · Cited by 81
Molecular predictors of response to chemotherapy in lung cancer
Rosell, R., Tarón, M., Ariza, A., et al. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.12.011 · Cited by 81
MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma
Guminski, A. D., Balleine, R. L., Chiew, Y.-E., Webster, L. R., Tapner, M. J., Farrell, G. C., Harnett, P. R., & DeFazio, A. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2005.08.046 · Cited by 80
Yahata, H., Kobayashi, H., Kamura, T., Amada, S., Hirakawa, T., Kohno, K., Kuwano, M., & Nakano, H. (2002) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-002-0386-6 · Cited by 80
Sharma, H., Sen, S., Muzio, L. L., Mariggiò, M. A., & Singh, N. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1783 · Cited by 76
Spierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401248 · Cited by 75
Graham, C. H., Kobayashi, H., Stankiewicz, K. S., Man, S., Kapitain, S. J., & Kerbel, R. S. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.13.975 · Cited by 73
Transcription factors and drug resistance
Kohno, K., Uchiumi, T., Niina, I., Wakasugi, T., Igarashi, T., Momii, Y., Yoshida, T., Matsuo, K.-I., Miyamoto, N., & Izumi, H. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.007 · Cited by 73
Some fundamental considerations of the applications of pharmacokinetics to cancer chemotherapy.
Bischoff, K. B. (1975) · PubMed · Cited by 73
Cross-resistance to cisplatin in cells with acquired resistance to copper
Safaei, R., Katano, K., Samimi, G., Naerdemann, W., Stevenson, J. L., Rochdi, M., & Howell, S. B. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0736-3 · Cited by 72
Nakayama, K., Miyazaki, K., Kanzaki, A., Fukumoto, M., & Takebayashi, Y. (2001) · Oncology Reports · doi:10.3892/or.8.6.1285 · Cited by 71
Restoring p53-Dependent Tumor Suppression
Wang, W., Rastinejad, F., & El‐Deiry, W. S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.203 · Cited by 71
Neuroendocrine differentiation as a prognostic factor in non-small cell lung cancer
Carles, J., Rosell, R., Ariza, A., Pellicer, I., Sanchez, J. J., Fernandez-Vasalo, G., Abad, A., & Barnadas, A. (1993) · Lung Cancer · doi:10.1016/0169-5002(93)90181-v · Cited by 70
FANCF methylation contributes to chemoselectivity in ovarian cancer
Olopade, O. I., & Wei, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00111-9 · Cited by 70
Johnson, S. W., Shen, D.-W., Pastan, I. H., Gottesman, M. M., & Hamilton, T. C. (1996) · Experimental Cell Research · doi:10.1006/excr.1996.0211 · Cited by 69
Xu, Z.-Y., Loignon, M., Han, F.-Y., Panasci, L., & Aloyz, R. S. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084053 · Cited by 69
The relationship between intracellular and extracellular pH in spontaneous canine tumors.
Prescott, D. M., Charles, H. C., Poulson, J. M., Page, R. L., Thrall, D. Ε., Vujaskovic, Z., & Dewhirst, M. W. (2000) · PubMed · Cited by 66
Wasenius, V.-M., Jekunen, A. P., Monni, O. M., Joensuu, H., Aebi, S., Howell, S. B., & Knuutila, S. (1997) · Genes Chromosomes and Cancer · Cited by 65
Menéndez, J. A., Mehmi, I., & Lupu, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3489 · Cited by 65
Peters, D. G., Freund, J., & Ochs, R. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0311 · Cited by 65
The Fanconi Anemia/BRCA Signaling Pathway: Disruption in Cisplatin-Sensitive Ovarian Cancers
D’Andrea, A. D. (2003) · Cell Cycle · doi:10.4161/cc.2.4.413 · Cited by 65
Sensitivity of testis tumour cells to chemotherapeutic drugs: Role of detoxifying pathways
Masters, J. R., Thomas, R., Hall, A. G., Hogarth, L., Matheson, E. C., Cattan, A. R., & Lohrer, H. D. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00033-0 · Cited by 64
Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells
Hövelmann, S., Beckers, T. L., & Schmidt, M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601876 · Cited by 63
Baldwin, R. M., Garratt-Lalonde, M., Parolin, D. A. E., Krzyzanowski, P. M., Andrade-Navarro, M. A., & Lorimer, I. A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209312 · Cited by 63
Richardson, A., & Kaye, S. B. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.09.001 · Cited by 63
Amaya, K., Ohta, T., Kitagawa, H., Kayahara, M., Takamura, H., Fujimura, T., Nishimura, G., Shimizu, K., & Miwa, K. (2004) · PubMed · Cited by 62
Human REV1 Modulates the Cytotoxicity and Mutagenicity of Cisplatin in Human Ovarian Carcinoma Cells
Lin, X., Okuda, T., Trang, J., & Howell, S. B. (2006) · Molecular Pharmacology · doi:10.1124/mol.105.020446 · Cited by 62
Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells.
Nagatani, G., Nomoto, M., Takano, H., Ise, T., Kato, K., Imamura, T., Izumi, H., Makishima, K., & Kohno, K. (2001) · PubMed · Cited by 62
p53 gene status and chemosensitivity in ovarian cancer.
Kigawa, J., Sato, S., Shimada, M., Takahashi, M., Itamochi, H., Kanamori, Y., & Terakawa, N. (2001) · PubMed · Cited by 61
Endo, T., Yoshikawa, M., Ebara, M., Kato, K., Sunaga, M., Fukuda, H., Hayasaka, A., Kondo, F., Sugiura, N., & Saisho, H. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-004-1471-1 · Cited by 60
Goswami, S. K., Wang, W., Wyckoff, J. B., & Condeelis, J. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2027 · Cited by 60
Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells
Liang, X., Mukherjee, S., Shen, D., Maxfield, F. R., & Gottesman, M. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3436 · Cited by 60
Mandić, R., Schamberger, C. J., Müller, J. F., Geyer, M., Zhu, L., Carey, T. E., Grenman, R. A., Dünne, A.-A., & Werner, J. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0378 · Cited by 60
Strozyk, E. A., Pöppelmann, B., Schwarz, T., & Kulms, D. (2006) · Oncogene · doi:10.1038/sj.onc.1209655 · Cited by 58
Nyce, J. W. (1997) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(96)00051-8 · Cited by 56
Modulation of Cellular Response to Cisplatin by a Novel Inhibitor of DNA Polymerase β
Boudsocq, F., Benaim, P., Canitrot, Y., Knibiehler, M., Ausseil, F., Capp, J., Bieth, A., Long, C., David, B., Shevelev, I., et al. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.001776 · Cited by 56
Lin, X., Trang, J., Okuda, T., & Howell, S. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1380 · Cited by 55
Two Nuclear Proteins, Cin5 and Ydr259c, Confer Resistance to Cisplatin in Saccharomyces cerevisiae
Furuchi, T., Ishikawa, H., Miura, N., Ishizuka, M., Kajiya, K., Kuge, S., & Naganuma, A. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.3.470 · Cited by 55
Wang, S. J., & Bourguignon, L. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.1.19 · Cited by 54
Camps, C., Sarries, C., Roig, B., et al. (2003) · Clinical Lung Cancer · doi:10.3816/clc.2003.n.004 · Cited by 54
Cabelguenne, A., Loriot, M., Stücker, I., Blons, H., Koum-Besson, E., Brasnu, D. F., Beaune, P. H., Laccourreye, O., Laurent‐Puig, P., & de Waziers, I. (2001) · International Journal of Cancer · doi:10.1002/ijc.1392 · Cited by 52
Role of the transcription factor Ets-1 in cisplatin resistance
Wilson, A., Yamamoto, H., & Singh, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.823.3.7 · Cited by 52
Stewart, D. J., Chiritescu, G., Dahrouge, S., Banerjee, S., & Tomiak, E. M. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2006.12.002 · Cited by 51
Self-citationBelfi, C. A., Chatterjee, S., Gosky, D. M., Berger, S. J., & Berger, N. A. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0472 · Cited by 50
Shen, D.-W., Su, A., Liang, X.-J., Panandiker, A. S. P., & Gottesman, M. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601956 · Cited by 49
Aberrant overexpression of 53BP2 mRNA in lung cancer cell lines
Mori, T., Okamoto, H., Takahashi, N., Ueda, R., & Okamoto, T. (2000) · FEBS Letters · doi:10.1016/s0014-5793(99)01726-3 · Cited by 48
Up-regulation of Bfl-1/A1 via NF-κB activation in cisplatin-resistant human bladder cancer cell line
Kim, J. K., Kim, K. D., Lee, E., Lim, J., Cho, H.-J., Yoon, H. K., Cho, M. Y., Baek, K. E., Park, Y. P., Paik, S., et al. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.02.021 · Cited by 48
Trenz, K., Lugowski, S., Jahrsdörfer, U., Jainta, S., Vogel, W., & Speit, G. (2003) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2003.06.011 · Cited by 47
Ray, P., Quantin, X., Grenier, J., & Pujol, J.-L. (1998) · Cancer Detection and Prevention · doi:10.1046/j.1525-1500.1998.cdoa43.x · Cited by 47
Leonhardt, H., & Grigoleit, H.-G. (1977) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00498562 · Cited by 47
Perry, W. L., Shepard, R. L., Sampath, J., Yaden, B. C., Chin, W. W., Iversen, P. W., Jin, S., Lesoon, A., O'Brien, K. A., Peek, V. L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-03-3675 · Cited by 47
Yang, X., Xing, H., Gao, Q., Chen, G., Lu, Y., Wang, S., & Ma, D. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.055 · Cited by 46
Fortin, A., Raybaud-Diogène, H., Têtu, B., Huot, J., Landry, J., & M.Sc, R. D. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00410-1 · Cited by 46
Min, J., Stegner, A. L., Alexander, H., & Alexander, S. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.3.795-805.2004 · Cited by 46
Kuin, A., Aalders, M. C. G., Lamfers, M. L. M., van Zuidam, D. J., Essers, M., Beijnen, J. H., & Smets, L. A. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690127 · Cited by 45
Lin, X., & Howell, S. B. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.2.390 · Cited by 45
Chen, Y., Yuan, C., Chow, K., Wang, P., Lai, C., Yen, M.-S., & Wang, L.-S. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.031 · Cited by 44
Ikuta, K., Takemura, K., Kihara, M., Nishimura, M., Ueda, N., Naito, S., Lee, E., Shimizu, E., & Yamauchi, A. (2005) · PubMed · Cited by 43
Targeting DNA mismatch repair for radiosensitization
Berry, S. E., & Kinsella, T. J. (2001) · Seminars in Radiation Oncology · doi:10.1053/s1053-4296(01)80067-9 · Cited by 43
Upadhyay, A. K., Singh, S., Chhipa, R. R., Vijayakumar, M. V., Ajay, A. K., & Bhat, M. K. (2006) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.05.009 · Cited by 43
Hsu, C., Gao, M., Chen, C., Yeh, P.-Y., & Cheng, A. (2005) · Oncology · doi:10.1159/000086998 · Cited by 42
Sensitization of Cancer Cells to DNA Damaging Agents by Imidazolines
Sharma, V., Peddibhotla, S., & Tepe, J. J. (2006) · Journal of the American Chemical Society · doi:10.1021/ja060273f · Cited by 42
Applications of genomics in NSCLC
Rosella, R., Cobo, M., Isla, D., et al. (2005) · Lung Cancer · doi:10.1016/s0169-5002(05)81571-5 · Cited by 42
Metallothionein in carcinogenesis and cancer chemotherapy
Ebadi, M., & Iversen, P. L. (1994) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(94)90152-x · Cited by 41
Prognostic value of overexpression of p53 in human ovarian carcinoma patients receiving cisplatin
Nakayama, K., Takebayashi, Y., Nakayama, S., Hata, K., Fujiwaki, R., Fukumoto, M., & Miyazaki, K. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00686-9 · Cited by 41
Ikuta, K., Takemura, K., Sasaki, K., Kihara, M., Nishimura, M., Ueda, N., Naito, S., Lee, E., Shimizu, E., & Yamauchi, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.707 · Cited by 40
Kato, K., Nomoto, M., Izumi, H., Ise, T., Nakano, S., Niho, Y., & Kohno, K. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(00)00168-8 · Cited by 40
Olasz, J., Mándoky, L., Géczi, L., Bodrogi, I., Csuka, O., & Bak, M. (2005) · PubMed · Cited by 40
Kim, S. B., Kim, J. S., Lee, J. H., Yoon, W. J., Lee, D. S., Ko, M. S., Kwon, B., Choi, D. H., Cho, H. R., Lee, B. J., et al. (2005) · FEBS Letters · doi:10.1016/j.febslet.2005.12.012 · Cited by 39
Nakamura, M., Nakatani, K., Uzawa, K., Ono, K., Uesugi, H., Ogawara, K., Shiiba, M., Bukawa, H., Yokoe, H., Wada, T., et al. (2005) · Oncology Reports · doi:10.3892/or.14.5.1281 · Cited by 38
Sun, C., & Chao, C. C. ‐. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008797 · Cited by 35
Pan, B., Yao, K.-S., Monia, B. P., Dean, N. M., McKay, R. A., Hamilton, T. C., & O'Dwyer, P. J. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00841-9 · Cited by 34
Matsumura, Y., Yamagishi, N., Miyakoshi, J., Imamura, S., & Takebe, H. (1997) · Cancer Letters · doi:10.1016/s0304-3835(97)04714-9 · Cited by 34
Mizutani, Y., NAKANISHI, H., Li, Y. N., Sato, N., Kawauchi, A., & Miki, T. (2004) · The Journal of Urology · doi:10.1097/01.ju.0000131945.74377.ad · Cited by 34
Vitamin C Enhances Chemosensitization of Esophageal Cancer Cellsin Vitro
Abdel-Latif, M., Raouf, A. A., Sabra, K., Kelleher, D. P., & Reynolds, J. V. (2005) · Journal of Chemotherapy · doi:10.1179/joc.2005.17.5.539 · Cited by 33
Sensitizing glioma cells to cisplatin by abrogating the p53 response with antisense oligonucleotides
Datta, K., Shah, P., Srivastava, T., Mathur, S. G., Chattopadhyay, P., & Sinha, S. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700724 · Cited by 33
Concentration-dependent collateral sensitivity of cisplatin-resistant gastric cancer cell sublines
Xu, H., Choi, S.-M., Choi, S.-M., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.01.015 · Cited by 32
Bérubé, M., Talbot, M., Collin, C., Paquet‐Bouchard, C., Germain, L., Guérin, S. L., & Petitclerc, É. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.2.405 · Cited by 30
Eichholtz-Wirth, H., & Sagan, D. (2000) · APOPTOSIS · doi:10.1023/a:1009656513307 · Cited by 29
Shinkai, T., Eguchi, K., Sasaki, Y., Tamura, T., Ohe, Y., Kojima, A., Oshita, F., & Saijo, N. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90220-8 · Cited by 29
Akita, H., Doki, Y., Miyata, H., Hirao, T., Yano, M., Takachi, K., Miyashiro, I., Sasaki, Y., Ishikawa, O., Ohigashi, H., et al. (2006) · Journal of Surgical Oncology · doi:10.1002/jso.20501 · Cited by 28
Genomic Imbalances Associated with Acquired Resistance to Platinum Analogues
Leyland-Jones, B. R., Kèlland, L. R., Harrap, K. R., & Hiorns, L. R. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65102-4 · Cited by 28
Li, F., Li, M., Zhou, J., Xing, H., Wang, S., Xu, G., Zhu, H., Wang, B., Chen, G., Lu, Y., et al. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.169 · Cited by 28
Passagne, I., Evrard, A., Depeille, P., Cuq, P., Cupissol, D., & Vian, L. (2005) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2005.06.009 · Cited by 27
Takano, M., Kudo, K., Gotō, T., Yamamoto, K., Kita, T., & Kikuchi, Y. (2001) · PubMed · Cited by 27
Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells
Wang, Z., Xie, Y., & Wang, H. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1782 · Cited by 25
Cited by
Metallodrugs in Medicinal Inorganic Chemistry
Mjos, K. D., & Orvig, C. (2014) · Chemical Reviews · doi:10.1021/cr400460s · Cited by 1,289
Platinum-based drugs: past, present and future
Dilruba, S., & Kalayda, G. V. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2976-z · Cited by 906
Platinum Resistance: The Role of DNA Repair Pathways
Martin, L. P., Hamilton, T. C., & Schilder, R. J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2238 · Cited by 751
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Anticancer Activity of Metal Complexes: Involvement of Redox Processes
Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 554
Metadata
- Authors
- Stewart, D. J.
- Venue
- Critical Reviews in Oncology/Hematology
- Publisher
- Elsevier BV
- Published
- 2007-07
- Volume
- 63
- Issue
- 1
- Pages
- 12-31
- ISSN
- 1040-8428 (ISSN-L)
- OpenAlex
- W2058977958
- Cited by
- 631
- References
- 217
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.